Prostatic Zn Determination for Prostate Cancer Diagnostic Value

Objective To investigate prostate tissue zinc combination of prostate-specific antigen(PSA) for prostate cancer diagnosis.Methods For prostate cancer treatment guidelines in line with the provisions of the prostate puncture indication system,the patients were examined by prostate biopsy,an organization dedicated by ICP-MS determination of the prostate tissue content of zinc,and the rest of the organization routine pathological examination.At the same time,the data of serum PSA,the prostate through the rectum color ultrasound,and the pathology of the prostate puncture were analyzed.Results According to the results of pathology,the patients were divided into benign prostatic hyperplasia and prostate cancer group.Prostatic hyperplasia(n=20):PSA:(6.691±5.920)ng/mL,prostate Zinc:(125.845±75.600)μg/g(wet).Prostate cancer group(n=22):PSA:(68.390±59.000)ng/mL,prostate tissue zinc content:(54.470±32.690)μg/g(wet).Prostate tissue zinc content comparison between the two groups was statistically significant(P0.05).Conclusion Prostate cancer zinc content was significantly lower than that of prostate hyperplasia.The prostate tissue content of zinc reduce prostate cancer diagnosis has a certain value.